Journal
FRONTIERS IN MICROBIOLOGY
Volume 14, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2023.1114226
Keywords
RVFV vaccine; glycoprotein; adenovirus serotype 5 vector; single-dose immunization; sterilizing protection; A129 mice
Categories
Ask authors/readers for more resources
This study focuses on Rift valley fever virus (RVFV), a bunyavirus transmitted by mosquitoes that causes severe diseases in animals and humans. The researchers developed a potential vaccine and tested its immunogenicity and protective efficacy in mice, showing promising results. However, further research is needed to confirm its efficacy in a natural animal host and to potentially progress as a vaccine candidate for humans.
Instruction: Rift valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe disease in animals and humans. Nevertheless, there are no vaccines applied to prevent RVFV infection for human at present. Therefore, it is necessary to develop a safe and effective RVFV vaccine.Methods: We generated Ad5-GnGcopt, a replication-deficient recombinant Ad5 vector (human adenovirus serotype 5) expressing codon-optimized RVFV glycoproteins Gn and Gc, and evaluated its immunogenicity and protective efficacy in mice.Results and Discussion: Intramuscular immunization of Ad5-GnGcopt in mice induces strong and durable antibody production and robust cellular immune responses. Additionally, a single vaccination with Ad5-GnGcopt vaccination can completely protect interferon-alpha/beta receptor-deficient A129 mice from lethal RVFV infection. Our work indicates that Ad5-GnGcopt might represent a potential vaccine candidate against RVFV. However, further research is needed, first to confirm its efficacy in a natural animal host, and ultimately escalate as a potential vaccine candidate for humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available